← Browse by Condition
Medical Condition

advanced hepatocellular carcinoma

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 3, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for advanced hepatocellular carcinoma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for advanced hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced hepatocellular carcinoma?
advanced hepatocellular carcinoma research spans Phase 1 (2 trials), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced hepatocellular carcinoma clinical trial?
Eligibility criteria for advanced hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Phase 3
1
Top Sponsors
Sun Yat-sen University 2 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 1 trial
University of Texas Southwestern Medical Center 1 trial
Pfizer 1 trial
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT06618664 Phase 3
Recruiting
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Enrollment
590 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti...
View Trial →
NCT06624098
Recruiting
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
Enrollment
22 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06789848 Phase 2
Recruiting
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Enrollment
64 pts
Location
United States
Sponsor
University of Texas Southweste...
View Trial →
NCT06644430
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Enrollment
470 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT07227012 Phase 1, Phase 2
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Enrollment
138 pts
Location
United States, Japan...
Sponsor
Pfizer
View Trial →
NCT05092373 Phase 1
Recruiting
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Enrollment
43 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

metastatic hepatocellular carcinoma (2) variceal bleeding (1) refractory hepatocellular carcinoma (1) biliary tract cancer (1) lung cancer (1) oligometastasis (1) ablation (1) systemic therapy (1) carcinoma hepatocellular (1) hepatocellular cancer (1) hepatocellular carcinoma (1) unresectable hepatocellular carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology